Daiken Medical Co., Ltd. announced non-Consolidated earnings guidance for the Six months ending September 30, 2021 and full year ending March 31, 2022. For the six months ending September 30, 2021, on the non-consolidated basis, the company expects, net sales of ¥4,350 million, operating profit of ¥510 million and profit of ¥360 million or ¥12.53 per share. For the full year ending March 31, 2022, on the non-consolidated basis, the company expects, net sales of ¥9,000 million, operating profit of ¥1,200 million and profit of ¥840 million or ¥29.24 per share.